Interleukin-17 (IL-17) Inhibitor in Combination With Tumor Necrosis Factor α (TNFα )Inhibitor for the Treatment of Ankylosing Spondylitis

Prior treatment

• Subjects who are participating in clinical research of other drugs;

Other illness

• With unstable vital signs, coma, mental and cognitive impairment;
• Patients with severe systemic diseases and other serious chronic diseases;
• History of malignant tumor in the past 5 years;
• Positive test for the following infection markers: human immunodeficiency virus (HIV), hepatitis B, hepatitis C, syphilis antibody;
• Patients with active or recurrent history of infection; With active tuberculosis or have a history of active tuberculosis in the past;
• Moderate to severe heart failure (New York Heart Association grade 3-4);
• Allergic to any of the components of adalimumab (HS016) or secukinumab;

Other

• Pregnant or lactating patients;
• In addition to the above, the investigator judged that there are other reasons that are not suitable for participating in this clinical study.

• Male or female at least 18 years old;
• diagnosed with AS according to the 1984 New York Modified Criteria;
• Poor response after at least 2 NSAIDs (cumulative treatment ≥ 4 weeks), or contraindication or intolerance to NSAIDs therapy;
• BASDAI score of ≥ 4 and total back pain VAS score of ≥ 4 at baseline;
• Subjects who need to take NSAIDs (including COX-1 or COX-2 inhibitors) as established treatment for AS, and the NSAIDs should be on a stable dose for at least 2 weeks (inclusive) before screening and the dose is expected to be stable during the study;
• Voluntary treatment with adalimumab and secukinumab;
• Appropriate contraceptive measures for women of childbearing age;
• without other rheumatic diseases.
• Able to understand study requirements, provide written informed consent, and comply with trial protocol procedures (including required visits)